

Updating OMERACT Core Set of Domains for ANCA-Associated Vasculitis: Patient Perspective Using the International Classification of Function, Disability and Health

Authors: Nataliya Milman (ORCID 0000-0002-7353-7007)^{1,2}, Eilish McConville³, Joanna C Robson (ORCID 0000-0002-7939-5978)^{4,5}, Annelies Boonen^{6,7}, Peter Tugwell^{1,2}, George A Wells⁸, Dipayan Chaudhuri³, Jill Dawson (ORCID 000-0002-2358-1333)⁹, Gunnar Tomasson^{10,11,12}, Susan Ashdown¹³, Don Gebhart^{14,15}, Georgia Lanier^{14,15}, Jacqueline Peck (ORCID 0000-0001-7981-459X)¹³, Carol A McAlear (ORCID 0000-0002-0016-6866)¹⁴, Katherine S Kellom (ORCID 000-003-0445-6614)¹⁶, Peter F Cronholm (ORCID 0000-0003-2570-7056)¹⁷, Peter A Merkel (ORCID 0000-0001-9284-7345)^{14,15}

Key Indexing Terms: OMERACT, vasculitis, outcome assessment

Institutions to which the work should be attributed:

1. Division of Rheumatology, Department of Medicine, and School of Epidemiology and Public Health, Faculty of Medicine, University of Ottawa;
2. Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada;
3. Department of Medicine, University of Ottawa / the Ottawa Hospital, Ottawa, Ontario, Canada;
4. Faculty of Health and Applied Science, University of the West of England, Bristol, UK;
5. School of Clinical Science, University of Bristol, Bristol, UK;
6. Maastricht University Medical Centre, Maastricht, the Netherlands;
7. Caphri Research Institute, Maastricht University, Maastricht, The Netherlands;
8. School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa Heart Institute, Ottawa, Ontario, Canada;
9. Nuffield Department of Population Health (HSRU), University of Oxford, Oxford, UK;
10. Department of Epidemiology and Biostatistics, Faculty of Medicine, University of Iceland, Reykjavik, Iceland;
11. Department of Rheumatology, University Hospital, Reykjavik, Iceland;
12. Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland;
13. Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK;
14. Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA;
15. Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA, USA;
16. PolicyLab, Children's Hospital of Philadelphia, 2716 South St, Philadelphia, PA 19146, USA;
17. Department of Family Medicine and Community Health, University of Pennsylvania, Philadelphia, PA, USA.

Sources of support:

The Vasculitis Clinical Research Consortium (VCRC) Outcome Measures in Rheumatology Vasculitis Working Group was supported by the Vasculitis Clinical Research Consortium, which received support from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (grants U54-AR-057319 and U01-AR-51874 04), the National Center for Research Resources (grant U54-RR-019497), the National Center for Advancing Translational Science, the Office of Rare Diseases Research, each part of the United States National Institutes of Health (NIH). The VCRC is a member of the NIH Rare Diseases Clinical Research Network. The VCRC also received a Pilot award from the Patient-Centered Outcomes Research

Institute. Dr. Milman's work was supported by a postgraduate Rheumatology Fellowship award given jointly by UCB Pharma, the Canadian Rheumatology Association, and The Arthritis Society, and a Fellowship from the Ottawa Hospital Department of Medicine. This work was further supported by a Vasculitis Foundation Research Grant.

Conflict of interest: none

Appointments:

N Milman, MD, MSc, FRCPC; Assistant Professor, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada;

E McConville, MD; Resident, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada;

JC Robson, MBBS, PhD, MRCP ; Consultant Senior Lecturer in Rheumatology, Faculty of Health and Applied Science, University of the West of England, Bristol, United Kingdom; School of Clinical Science; University of Bristol, Bristol, United Kingdom;

A Boonen, MD, PhD: Professor department of Medicine, Division of Rheumatology, Maastricht University Medical Centre, Maastricht, The Netherlands; Caphri Research Institute, Maastricht University, Maastricht, The Netherlands;

P Tugwell, MD, FRCPC; Professor, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada;

GA Wells, PhD; Professor, School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa Heart Institute, Ottawa, Ontario, Canada;

D Chaudhuri, MD; Resident, Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada;

J Dawson, MA, MSc, DPhil; Visiting Academic Researcher, Nuffield Department of Population Health (HSRU), University of Oxford, Oxford, UK;

G Tomasson, MD, PhD; Assistant Professor, Department of Epidemiology and Biostatistics, Faculty of Medicine, University of Iceland, Reykjavik Iceland;

S Ashdown, patient partner, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK;

D Gebhart, patient partner, Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA, USA;

G Lanier, patient partner, Division of Rheumatology, Department of Medicine, University of Pennsylvania, Philadelphia, PA, USA; Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA, USA;

J Peck, patient partner, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK;

CA McAlear, MA; Project Manager, Vasculitis Clinical Research Consortium, University of Pennsylvania, Philadelphia, PA, USA;

KS Kellom, BA; PolicyLab, Children's Hospital of Philadelphia, 2716 South St, Philadelphia, PA 19146, USA;

PF Cronholm, MD, MSCE; Associate Professor of Family Medicine and Community Health at Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA;

PA Merkel, MD, MPH; Professor, Division of Rheumatology and Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA, USA.

Corresponding author:

Nataliya Milman, nmilman@toh.ca

The Ottawa Hospital, Riverside Campus,
1967 Riverside Drive, Ottawa, ON K1H7W9,
Canada

Running head: Patient perspective on AAV

ABSTRACT

Objective: Aspects of ANCA-associated vasculitis (AAV) prioritized by patients with AAV were described using the International Classification of Function, Disability, and Health. Methods: Items identified during 14 individual interviews were incorporated into ICF-based questionnaire administered to participants of 2 vasculitis patient symposia, 36 in UK and 63 in USA. Results: Categories identified as at least “moderately relevant” by $\geq 5\%$ of subjects included 44 body functions, 14 body structures, 35 activities and participation, 31 environmental factors, and 38 personal factors. Conclusion: Identified categories differ from those captured by the current OMERACT core set and those prioritized by vasculitis experts.

INTRODUCTION

The vasculitides are a group of heterogeneous conditions characterized by inflammation of blood vessels. ANCA-associated vasculitis (AAV) are small vessel vasculitides that include granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and eosinophilic granulomatosis with polyangiitis (EGPA). AAV can affect practically any organ system, with manifestations ranging from disease limited to ears, nose, and sinuses to life-threatening failure of kidneys, lungs, or heart.

Outcome Measures in Rheumatology (OMERACT) is an international organization that strives to develop data-driven, optimal outcome measures for use in clinical trials (1). In 2010 OMERACT endorsed a Core Set of Outcome Measures for ANCA-Associated Vasculitis (2). Subsequently, a framework was developed for selection of areas and domains that should be assessed in clinical trials, referred to as the OMERACT Filter 2.0 framework (1,3); it calls for inclusion of a range of stakeholders, especially patients, into the process of outcome measure development.

The OMERACT Vasculitis Working Group has conducted several projects aimed at updating and expanding the existing expert-driven OMERACT Core Set for AAV(4,5), including this project which utilizes the International Classification of Function, Disability and Health (ICF). The ICF is a general health status framework (6) that views health as a broad concept shaped by the relationship between various ICF components: impairments of body functions and body structures, limitations of activities, restrictions of participation and the influence of environmental and personal contextual factors (6). ICF also offers a classification system to describe functioning and health using categories organized into a four-level hierarchically nested structure (6). The OMERACT initiative endorsed ICF as a tool to identify and classify (sub)-domains relevant to measurement of outcomes for a specific medical condition (1).

This manuscript describes the ICF-based analysis of aspects of health prioritized by patients with AAV.

METHODS

The study consisted of two parts, both overseen by a steering committee comprised of content experts, methodologists, including qualitative experts, and patients with AAV. The research received approval from the Ottawa Hospital's Research Ethics Board (protocol # 20120604-01H and 20150189-01H), and all participating patients gave informed consent.

The first, qualitative, part of the study, consisted of a series of individual semi-structured interviews conducted with English-speaking adult patients with AAV at the Ottawa Hospital in Ottawa, Canada and the Nuffield Orthopaedic Centre in Oxford, United Kingdom (UK). A purposive sampling strategy was used to select interviews for this study and aimed at including patients with each of the 3 types of AAV, with different severities, and at different stages of disease (7); interviews were performed until saturation of the identified concepts was reached (8).

Interviews were audio recorded, professionally transcribed, and all basic concepts were "linked" to the most precise ICF category according to previously established ICF linking rules by Cieza et al (9,10), and then summarized on the 2nd ICF level, as we described previously (11). As personal factors are currently not classified by the ICF, the general scheme proposed by Geyh et al (12) was followed. It divides the personal factors into 3 broad groups: 1) "facts" about the individual's position in the physical, social, and temporal context, 2) "experience" of the concept in question (feelings, thoughts, beliefs and motives,) and 3) "patterns" of experience and behaviour including personality traits and habits.

In the second part of the study, categories identified through the qualitative analysis were incorporated into an ICF-based questionnaire that was administered to participants of 2 vasculitis patient symposia: International Vasculitis and ANCA Workshop in London, UK, April 18, 2015 and the Vasculitis Foundation symposium in Jacksonville FL, USA, June 19-21, 2015. Participants rated the relevance of each listed category on a standardized ordinal scale associated with the ICF classification (6). The physiologic

effects of vasculitis and its effects on patients' activities were rated on a 5-level scale from 0 to 4 with the following categories: "no effect," "mild," "moderate," "severe," and "complete impairment." The relevance of environmental and personal factors was rated on a 9-level scale from -4 ("extreme negative effect on health"), through the same gradations to 0 ("no effect"), and then to +4 ("extreme positive effect"). Factors that have at least "moderate" effect for at least 5% of respondents were selected, as suggested previously (13).

RESULTS

Fourteen individual interviews (10 from Ottawa, Canada and 4 from Oxford, UK) were available for the qualitative portion of the study. Participants identified a wide range of important aspects of AAV that were linked to 159 ICF categories.

The underpinning qualitative findings were incorporated into a questionnaire administered to approximately 100 participants at each of the 2 vasculitis patient symposia described above; 51 and 74 patients from the UK and USA returned the questionnaire, and 36 and 63 (respectively) had AAV and were included in this analysis. Participants' demographic and clinical characteristics are summarized in **Supplementary Table 1**; the respondents' disease spectrum was representative of a general population of patients with AAV.

All of the categories presented in the questionnaire were rated as at least "moderately relevant" by at least 5% of subjects. This includes 44 second-level categories in the ICF component body functions, 14 in body structures, 35 in activities and participation, 31 in environmental factors, and 38 in personal factors. A subset of the most relevant categories, ranked as at least "moderately relevant" by at least 30% of participants, is summarized in **Tables 1-3**.

A greater proportion of participants from the USA compared to the UK reported financial situation and healthcare system issues, such as access to medications, as relevant to their health (38% and 60% versus 19% and 44%, respectively). Similarly, more American participants reported positive effects of having vasculitis (personal factors -> experience of vasculitis), including increased appreciation of life, increased sensitivity to other people's misfortunes, and increasing activities related to helping others (72%, 73%, and 64% versus 42%, 36%, and 39%, respectively). In contrast, the effect of the vasculitis on patients' ability to travel (activities and participation -> recreation and leisurely activities) was reported as at least moderately relevant by 61% of participants from the UK compared to 29% of Americans.

Similar analyses by type of AAV demonstrated expected trends: more respondents with EGPA reporting effect of their disease on the heart and lungs and a prominent impact of air quality (consistent with asthma being a central feature of the disease); subjects with MPA had the most difficulty with blood pressure and kidneys. Furthermore, subjects with MPA seemed to be most affected by the various aspects of their psychosocial functions, including mental functions (motivation, appetite, concentration, and emotions); domestic, community, and social life (activities and participation), and interpersonal interactions and relationships (environmental factors.)

DISCUSSION

In this analysis mainly limited by the narrow geographic sampling, the ICF was a useful framework for describing aspects of AAV relevant to patients. Comparisons of prioritized items by country of residence and by diagnosis revealed that while the majority of differences between the 3 different forms of AAV were in keeping with the expected differences in the frequencies of specific organ involvement, most variability between the 2 participating countries was seen in the importance of various contextual factors. As the role of contextual factors in interpreting outcome measures continues to be clarified (14),

considering some key contextual factors will deepen the ability to fully assess the impact of AAV and other diseases.

An earlier ICF-based analysis of the current OMERACT Core Set for AAV (11) revealed that it does not measure the whole spectrum of limitations in activities and participation prioritized by patients in this study, and covers only a small number of environmental and personal factors, likely because contextual factors have only recently become recognized as relevant for interpreting the measured outcomes (14). The areas under-sampled by the core set were also found to be less important to vasculitis clinical experts in a recent ICF-based analysis (15); this is not surprising, given that the composite tools that constitute the current OMERACT Core Set for AAV were designed by the same clinical experts. Notably, the few contextual factors that clinicians did identify as important differ from those prioritized by patients: clinicians focus on hard “objective” factors such as demographics, comorbidities, availability of health services, and social support (15), while the range of factors identified by patients is much broader and dominated by the more subjective factors such as attitudes of other people and patients’ own reactions and thoughts. In contrast, several of the more severe disease manifestations of AAV, such as lung and kidney involvement, visual impairment, and hearing loss, that are prioritized by the majority of vasculitis clinical experts (15) were rated as at least “moderately relevant” by <50% of patient participants, likely reflecting the frequency of these manifestations in the cohort. Along with similar findings in other studies (16), the observed differences in perspectives of patients and clinicians support OMERACT’s recommendation to include perspectives of different stakeholders, including patients, into the process of development of core sets of domains and outcome measures (1). To comply with these standards, the OMERACT Vasculitis Working Group is working to update the current OMERACT core set for AAV.

Acknowledgements: The authors appreciate the assistance and advice of Susan Humphrey-Murto, Joyce Kullman, John Mills, Susan Mills, and C. Douglas Smith.

REFERENCES

1. Boers M, Kirwan JR, Wells G, Beaton D, Gossec L, d'Agostino MA et al. Developing core outcome measurement sets for clinical trials: OMERACT filter 2.0. *J Clin Epidemiol* 2014;67:745-753.
2. Merkel PA, Aydin SZ, Boers M, Direskeneli H, Herlyn K, Seo P, et al. The OMERACT core set of outcome measures for use in clinical trials of ANCA-associated vasculitis. *J Rheumatol* 2011;38:1480-6.
3. Boers M, Kirwan JR, Tugwell P, Beaton D, Bingham CO III, Conaghan PG, et al. The OMERACT Handbook. [Internet. Accessed August 24, 2018.] Available from: <https://omeract.org/resources>.
4. Robson JC, Tomasson G, Milman N, Ashdown S, Boonen A, Casey GC et al. OMERACT endorsement of patient-reported outcome instruments in ANCA-associated vasculitis. *J Rheumatol* 2017;44:1529-1535.
5. Merkel PA, Aydin SZ, Boers M, Cornell C, Direskeneli H, Gebhart D et al. Current status of outcome measure development in vasculitis. *J Rheumatol* 2014;41:593-598.
6. World Health Organization. ICF-international classification of functioning, disability and health. Geneva: World Health Organization Library; 2001.
7. Robson JC, Dawson J, Cronholm PF, Milman N, Kellom KS, Ashdown S et al. Health-related quality of life in ANCA-associated vasculitis and item generation for a disease-specific patient-reported outcome measure. *Patient Relat Outcome Meas* 2018;9:17-34.
8. Kerr C, Nixon A, Wild D. Assessing and demonstrating data saturation in qualitative inquiry supporting patient-reported outcomes research. *Expert Rev Pharmacoecon Outcomes Res*. 2010;10:269-81.
9. Cieza A, Brockow T, Ewert T, Amman E, Kollerits B, Chatterji S et al. Linking health-status measurements to the international classification of functioning, disability and health. *J Rehabil Med* 2002;34:205-210.
10. Cieza A, Geyh S, Chatterji S, Kostanjsek N, Ustun B, Stucki G. ICF linking rules: an update based on lessons learned. *J Rehabil Med* 2005;37:212-218.
11. Milman N, Boonen A, Merkel PA, Tugwell P. Mapping of the outcome measures in rheumatology core set for antineutrophil cytoplasmic antibody-associated vasculitis to the International Classification of Function, Disability and Health. *Arthritis Care Res* 2015;67:255-263.
12. Geyh S, Muller R, Peter C, Bickenbach JE, Post MW, Stucki G et al. Capturing the psychologic-personal perspective in spinal cord injury. *Am J Phys Med Rehabil* 2011;90:S79-96.
13. Cieza A, Hilfiker R, Boonen A, van der Heijde D, Braun J, Stucki G. Towards an ICF-based clinical measure of functioning in people with ankylosing spondylitis: a methodological exploration. *Disabil Rehabil* 2009;31:528-537.
14. Finger ME, Boonen A, Woodworth TG, Escorpizo R, Christensen R, Nielsen SM et al. An OMERACT initiative toward consensus to identify and characterize candidate contextual factors: report from the contextual factors working group. *J Rheumatol* 2017;44:1734-1739.
15. Milman N, Boonen A, Tugwell P, Merkel PA. Clinicians' perspective on key domains in ANCA-associated vasculitis: a Delphi exercise. *Scand J Rheumatol* 2017;46:112-117.

16. Herlyn K, Hellmich B, Seo P, Merkel PA. Patient-reported outcome assessment in vasculitis may provide important data and a unique perspective. *Arthritis Care Res* 2010;62:1639-1645.